Lonza virtual Symposium, hosted by the MassBioHub
Digitally delivered | Tuesday 27 October 2020
Gain insight and discuss the challenges of early stage biopharmaceutical development
Lonza and the MassBioHub are pleased to invite you to join us for a complimentary virtual symposium to gain insight from experts in the different approaches and techniques to successfully progress biotherapeutic candidates from discovery to the clinic. Hear about updates on enhancements to new and established technologies enabling translational research. The day includes talks from industry experts, local biotech companies and technical specialists from Lonza.
Our networking breaks and virtual lunch offers the opportunity to speak with fellow scientists, presenters and Lonza specialists. During the symposium, you will have the opportunity to book a 1-on-1 consultation session with our scientific experts to be held in the days following the symposia.
Attendance at this event is complimentary for biotechs developing biopharmaceuticals and by invitation only. For more information, including the latest agenda and to register:
Insight and discussion with our experts
Agenda (Eastern Standard Time)
|08.30 am – 08.45 am||Welcome and overview of symposium
Kendalle Burlin O'Connell | COO MassBio
Moderator: Dr. Hari Kumar | Pharmaceutical Executive, Independent Board Member, former CEO Adheron Therapeutics
|08.45 am – 09.20 am||Keynote presentation
Dr. Robert Langer | Institute Professor, MIT Langer Research Laboratories
|09.20 am – 9.45 am||Local company presentation|
|9:45 am – 10.20 am||
Early developability assessment tools – Successful de-risking strategies to support progression of biologics from discovery to development
|10.20 am – 10.35 am||Virtual networking
|10.35 – 11.05 am||An approach for successful tech transfers of pre-IND programs to CDMOs
Matt Wallace | Senior Director of CMC Operations, Jounce Therapeutics
|11.05 am – 11.55 am
||Approaches to maximize successful development of cell lines expressing a diverse range of proteins
Dr. Alison Porter | Head of Expression System Sciences, Lonza
|11.55 am – 12.10 pm
|12.10 pm – 12.35 pm
Dr. Patrick Doyle | CEO
|12.35 pm – 1.05 pm
||A multiplex approach for generating a potent autologous adoptive cellular immunotherapy for treating cancer
Dr. Frank Borriello | Founder & CEO, Alloplex Biotherapeutics, Inc.
|1.05 pm – 1.10 pm
||Wrap up and end of symposia|
For more information, including the latest agenda and to register:
This event is complementary for biotechs developing biopharmaceuticals and by invitation only.